BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 26155391)

  • 1. PDL1 expression is an independent prognostic factor in localized GIST.
    Bertucci F; Finetti P; Mamessier E; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D
    Oncoimmunology; 2015 May; 4(5):e1002729. PubMed ID: 26155391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.
    Bertucci F; Finetti P; Perrot D; Leroux A; Collin F; Le Cesne A; Coindre JM; Blay JY; Birnbaum D; Mamessier E
    Oncoimmunology; 2017; 6(3):e1278100. PubMed ID: 28405501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response.
    de Nonneville A; Finetti P; Picard M; Monneur A; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D; Mamessier E; Bertucci F
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of PDL1 expression in pancreatic cancer.
    Birnbaum DJ; Finetti P; Lopresti A; Gilabert M; Poizat F; Turrini O; Raoul JL; Delpero JR; Moutardier V; Birnbaum D; Mamessier E; Bertucci F
    Oncotarget; 2016 Nov; 7(44):71198-71210. PubMed ID: 27589570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Grade Index predicts postoperative clinical outcome of GIST.
    Bertucci F; Finetti P; Ostrowski J; Kim WK; Kim H; Pantaleo MA; Astolfi A; Polkowski M; Birnbaum D
    Br J Cancer; 2012 Oct; 107(8):1433-41. PubMed ID: 22929880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment.
    Wang YL; Gong Y; Lv Z; Li L; Yuan Y
    J Cancer; 2021; 12(6):1698-1707. PubMed ID: 33613757
    [No Abstract]   [Full Text] [Related]  

  • 7. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
    Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
    Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed cell death ligand 1 expression in osteosarcoma.
    Shen JK; Cote GM; Choy E; Yang P; Harmon D; Schwab J; Nielsen GP; Chebib I; Ferrone S; Wang X; Wang Y; Mankin H; Hornicek FJ; Duan Z
    Cancer Immunol Res; 2014 Jul; 2(7):690-698. PubMed ID: 24866169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
    Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
    Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
    Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Billon E; Finetti P; Bertucci A; Niccoli P; Birnbaum D; Mamessier E; Bertucci F
    Oncoimmunology; 2019; 8(11):e1655362. PubMed ID: 31646101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung.
    Igarashi T; Teramoto K; Ishida M; Hanaoka J; Daigo Y
    Oncol Rep; 2017 Oct; 38(4):2189-2196. PubMed ID: 28791392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.
    Rusakiewicz S; Semeraro M; Sarabi M; Desbois M; Locher C; Mendez R; Vimond N; Concha A; Garrido F; Isambert N; Chaigneau L; Le Brun-Ly V; Dubreuil P; Cremer I; Caignard A; Poirier-Colame V; Chaba K; Flament C; Halama N; Jäger D; Eggermont A; Bonvalot S; Commo F; Terrier P; Opolon P; Emile JF; Coindre JM; Kroemer G; Chaput N; Le Cesne A; Blay JY; Zitvogel L
    Cancer Res; 2013 Jun; 73(12):3499-510. PubMed ID: 23592754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].
    Li XQ; Tu L; Wang M; Ma XL; Yang LX; Shen YY; Zhuang C; Zhao WY; Qiu JF; Zhao G; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):872-879. PubMed ID: 32927512
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas.
    Tabanelli V; Corsini C; Fiori S; Agostinelli C; Calleri A; Orecchioni S; Melle F; Motta G; Rotili A; Di Napoli A; Pileri SA
    Hum Pathol; 2019 Aug; 90():60-69. PubMed ID: 31125630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.
    Paré L; Pascual T; Seguí E; Teixidó C; Gonzalez-Cao M; Galván P; Rodríguez A; González B; Cuatrecasas M; Pineda E; Torné A; Crespo G; Martin-Algarra S; Pérez-Ruiz E; Reig Ò; Viladot M; Font C; Adamo B; Vidal M; Gaba L; Muñoz M; Victoria I; Ruiz G; Viñolas N; Mellado B; Maurel J; Garcia-Corbacho J; Molina-Vila MÁ; Juan M; Llovet JM; Reguart N; Arance A; Prat A
    Ann Oncol; 2018 Oct; 29(10):2121-2128. PubMed ID: 30165419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma.
    Jlassi A; Rejaibi R; Manai M; Sahraoui G; Guerfali FZ; Charfi L; Mezlini A; Manai M; Mrad K; Doghri R
    Front Oncol; 2024; 14():1352053. PubMed ID: 38634058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.